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Abstract
Human immunodeficiency virus (HIV), with about 30 million deaths and double infections (in 
developing countries),  is  an  open challenge today for  global  scientists.  Developing safe and 
effective  measurements  against  it  has become the prime need of hour.  Though,  putting it  at 
health priority, various efforts like chemotherapy, vaccines and others are attempted globally 
over last decade. Consequently, highly active antiretroviral therapy was introduced but fails to 
completely  block  the  viral  replication  due  to  drug  resistance  and  various  other  severe  side 
effects.  The  antigenic  variability  and  lack  of  appropriate  experimental  models  is  the  major 
obstacle in the development of an ever effective treatment against HIV. However, to overcome 
the present hurdles and to emerge a preventive HIV vaccine efforts at various platforms are done. 
A renewed, coordinated research, preclinical studies, clinical trials together with sufficient long 
term scientific and commercial commitments are made. Few of the therapeutic efforts viz. RNA 
interference (RNAi) based replication arrest of HIV, viral enzymes’ inhibitors, nanotechnology 
based HIV control and various preclinically trialed vaccines are reviewed in this paper. Also, the 
observed toxicity of existing therapeutic regimen, key challenges and future prospects for the 
development of better tolerated prophylactic HIV-1 vaccine are discussed.
Key words: HAART, HIV-1 vaccine, RNAi, HIV enzyme inhibitors. 
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1. Introduction
HIV is a silent killer of human beings. People with contagion of HIV may have no symptoms 
for about 10 years, but tend to surpass the infectivity to others (Piot et al., 2007; Del Rio et 
al., 2009; Sterling et al., 2009). Since, it lysogenically invades and hides itself into the host 
cell’s  genome  therefore  it  may  remains  asymptomatic  for  long  time.  Nevertheless,  by 
integrating and mutating the genome further it disables the body’s defense system through 
infecting the TH, Macrophages and Dendritic cells (Cunningham et al. 2010). Structurally the 
HIV is an enveloped RNA virus containing 72 little projections of glycoprotein 120 and 41 
on cell surface. Also, protein p17 lies beneath the matrix and bullet shaped viral core made 
from protein p24 is found around the genetic material (Nielsen et al., 2005).
The  cellular  receptors  CD4 and  chemokine  receptors  CCR5  or  CXCR4  expressed  on 
Macrophages and TH cells’ surface are targeted by HIV-1 to bind with gp120 followed by 
conformational change in gp41 for fusion of virus-cell membrane to host cell and entry of 
nucleocapsid into cytoplasm (Eckert et al., 2001; Platt et al., 2005; Ray et al., 2006).  Then 
virally  encoded enzyme Reverse Transcriptase (RT) converts  the viral RNA genome into 
proviral DNA (Coffin et al., 1997), which on entering into nucleus gets covalently integrated 
with the genome of host cell by the activity of another virally encoded enzyme Integrase (IN) 
(Mitchell et al., 2004; Scherdin et al, 1990; Schroder et al, 2002). Now it serves as template 
for  viral  transcription (Coffin  et  al,  1997).   Consequently,  the  expressed  core  proteins 
processed through viral proteases into morphologically changed structure (Coffin et al. 1997; 
Zhu et al, 1993) to produce new viral progeny and augmenting the infection.
The latent ability of HIV to hide itself into host cell and to bring variations in its genetic  
composition has made it difficult for human defense system to find and attack on it (Chun et 
al. 1999). Hence, the type of treatment imperatively needed is, which could only kill the virus 
without affecting host cells. Though, involving HAART and some other antiviral substances 
viz. interferon have been effective in preventing virus from budding. Moreover, scientists are 
exploring the preventive role of viral enzymes, protein molecules and RNA interference as 
well. Above all, development of simplest, safest, and more effective vaccine which could 
interfere the viral interactions with host body in any way is also attempted.
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2. Targeting the HIV and host cell interaction 
Since, it is tough to get rid off from virus once entered in host body therefore blockade of 
entry of HIV while interacting with its surface glycoprotein to CCR5 and CXCR4 chemo 
receptors of CD4+ and Macrophage cells, are endeavored. Consequently, an antagonist TAK-
779 specific to CCR5 was introduced to compete with gp 120 during HIV infection (Dragic 
et  al.  2000).  Moreover,  some  other  inhibitors  like  anti-CD4-IgG2,  PRO  140  and  T-20, 
inhibiting to  HIV-1 attachment,  CCR5 usage and fusion respectively,  have undergone for 
testing with diverse primary cells types that represent the major targets for both infection in 
vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. 
(Ketas et  al.  2003). A small  compound  BMS-378806 had been discovered that  bind with 
gp120 of HIV-1 and block its entry into host cells by inhibiting interactions between gp120 
and  CD4+  receptor  molecule  (Lin  et  al.  2003).  This  can  be  orally  administered  in 
combination with other drugs to attain utmost anticipation of HIV-1 infection (Kadow et al. 
2006).  Besides  this,  a  tetravalent  CD4-immunoglobulin  protein,  PRO  542  (CD4-
immunoglobulin G2) has also been developed which similarly bind to gp120 and blocks the 
attachment and entry of virus into CD4+ cells (Jacobson et al. 2004). It has  demonstrated 
good antiviral activity by reducing viral RNA levels without any significant toxicity in tested 
candidates. Interestingly, its greater antiviral effects were observed among advanced HIV-1 
patients. (Jacobson et al., 2004). Meanwhile some other gp 120 inhibitors potent to prevent 
its conformational changes during infection were also developed.
Advancements  of  entry  inhibitors  is  the  latest  trend  in  the  progression  of  antiretroviral 
compounds, a fusion inhibitor Efuvirtide is the first to get approval in this regard (Briz et al. 
2006),  and  several  other  are  near  to  clinical  approach  and  hopefully  soon  be  a  part  of 
therapeutic treatment. 
3. Impeding the HIV replication by viral enzyme inhibition
Current  HIV-1  treatments  given  are  the  combination  of  drugs  targeting  to  Reverse 
Transcriptase (RT), Protease (PR) and Integrase (IN). At present, 22 compounds have been 
formally  approved  by  the  US  Food  and  Drug  Administration  for  the  treatment  of  HIV 
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infections  (De  Clercq,  2009). Since,  RT,  PR  and  IN  are  essential  enzymes  for  viral 
replication hence their arrested expression is thought as better alternative way to stop viral 
growth in host cell (Andréola  et al. 2002).  The combination of these enzyme inhibitors is 
found capable to reduce viral load for extended duration and slowing the disease progression 
as well (Reeves et al. 2005).
In addition to above, following other events of HIV replication cycle are also considered as 
potential targets for chemotherapeutic interventions (De Clercq 2002). 
(i) Viral  adsorption;  through  binding  to  the  viral  envelope  glycoprotein  gp120 
(polysulfates,  polysulfonates,  polycarboxylates,  polyoxometalates,  polynucleotides, 
and negatively charged albumins) 
(ii) Viral  entry;  through  blockade  of  viral  co-receptors  CXCR4  (i.e.,  bicyclam 
(AMD3100) derivatives) and CCR5 (i.e., TAK-779 derivatives) 
(iii)  Virus–cell fusion; through binding to the viral envelope glycoprotein gp41 (T-
20, T-1249)
(iv) Viral  assembly  and disassembly;  through NCp7 zinc finger-targeted  agents  (2,2′-
dithiobisbenzamides (DIBAs), azadicarbonamide (ADA)) 
(v) Proviral  DNA  integration;  through  integrase  inhibitors  such  as  4-aryl-2,4-
dioxobutanoic acid derivatives
(vi) Viral  mRNA  transcription;  through  transcription  inhibitors  (flavopiridol, 
fluoroquinolones). 
However, regular doses of these drugs often cause mild side effects  and sometimes even 
serious also which can impact on health or quality of life. The abuses of them vary from 
appetite  loss,  fatigue,  insomnia,  diabetes,  nephrotoxicity,  lactic  acidosis,  hepatotoxicity, 
pancreatitis,  hypercholesterolemia,  diarrhea,  peripheral  neuropathy  (nerve  damage), 
lipodystrophy to effect on central nervous system (Ian, 2005).
4. Inhibition of HIV infection by RNA interference
RNAi, with its interfering ability is become a hot point for current research approaches. It  
was  first observed in lower organisms such as plants, C. elegans, Drosophila and Protozoans, 
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in which double stranded RNA (dsRNA)  are digested into short double-stranded interfering 
RNA  (siRNA)  which  then  combine  with  endonucleases  and  form  complexes  to  target 
homologous mRNA and degrade them (Bennasser, 2005).
In order to use RNAi as therapeutic tool against HIV-1 work is done by Jacque et al. 2002 
and reported that duplexes of 21-23bp in length of plasmid-derived siRNA could target HIV-
1 genome so that HIV-1 replication in early and late stages can be inhibited and viral cDNA 
intermediates cannot be formed. Therefore, RNAi is thought a better tool to use against HIV 
multiplication in infected cells  especially  when its genome is also the RNA (Rossi et  al. 
2002). 
5. Active immunization by therapeutic vaccines 
The concept of therapeutic immunization against HIV-1, as an alternative to HAART, was 
brought  into focus by the polio vaccine  pioneer  Jonas Salk in 1987. Since,  it  allow less 
medication and scheduled holiday treatment therefore scientific workforce of nearly entire 
world involved to  crack the mystery and to  develop an ever  effective  and safer  vaccine 
against HIV-1. Million of science brains employed to understand the various mechanism viz. 
cellular and molecular regulation of viral gene expression, viral  entry into host cell,  HIV 
replication, development of improved HIV envelope immunogens, assembly of viruses, and 
others  for  developing  the  HIV-vaccine. As  a  result,  several  attempts  were  executed  as 
vaccines and clinically trialed but only few of them got bit success, are reviewed below. 
Furthermore the unique qualities needed to be an ideal HIV vaccine and major obstacles in 
its development are also discussed.
5.1 Vaccines 
5.1.1 Whole Inactivated HIV Vaccines
Remune, a purified and inactivated HIV-1 particle is used as vaccine and found able to give 
HIV-specific cell-mediated immune responses in 48% of AIDS patients (Egan, 2005). The 
greater effect of it was shown in the people who have undergone clinical treatment over the 
period of 6 years for strengthening the immune responses (Egan, 2005). However, conclusion 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
54
0.
1 
: P
os
te
d 
12
 J
an
 2
01
1
regarding Remune treatment efficacy could not be made because of the lack of control of 
patients who did not received vaccine trials. But it had proved the immune potency in adults 
who were given Remune alone, or in combination with antiretroviral therapy (Egan, 2005).
5.1.2 Virus-like Particle   Vaccines
According to a study done by Lindenburg et al., in 2002, some HIV structural proteins like 
Gag  were  reported  capable  of  assembling  themselves  into  virus-like  particles,  when 
expressed  alone  and  elicit  HIV-specific  immune  responses  in  animals  without  HIV-1. 
However, as a therapeutic vaccine they failed to reveal clinical benefits.
5.1.3 Recombinant Protein Vaccines
In  year  1991,  augmentation  of  active  immunization  against  HIV-1  with  molecularly 
engineered,  or  recombinant,  viral  proteins  was  also  attempted.  In  this  study,  a  vaccine 
(VaxSyn) comprised of recombinant  HIV-1 gp160 was tested on untreated 30 individuals 
infected  with HIV-1. Encouragingly,  63% individuals,  received 6 doses of vaccine,  were 
developed immunity in its response at initial level of trial (Tsoukas et al., 1998). However, 
larger efficacy trial on 278 healthy, untreated HIV-1 infected individuals did not provide any 
clinical  benefit.  Also,  any alteration  in  CD4+ cell  loss,  HIV-1 viral  load,  progression  to 
AIDS-defining  illness,  time  to  initiation  of  HAART,  or  time  to  death  was  not  observed 
(Tsoukas  et  al.,  1998).  Conclusively,  VaxSyn  gp160 was  found  lesses  effective  than 
antiretroviral monotherapy on clinical markers of disease progression (Tsoukas et al., 1998).
5.1.4 Peptide Vaccines
A number of synthetic viral peptides (fragments of entire viral proteins) have also been tested 
as potential therapeutic vaccines against HIV-1. In these approaches, specific viral sequences 
such  as  NK  receptors’  complementary  region  and  area  responsible  to  generate  HIV 
neutralizing  antibody  are  often  targeted  to  generate  immune  response.  One  such  HIV 
envelope-derived peptide vaccine C4-V3 consisting of four synthetic peptides has been tested 
for  its  efficacy.  Each  unit  of  vaccine  contains  viral  regions  known to  stimulate  cellular 
immune  responses  and  to  generate  HIV-neutralizing  antibody  responses  as  well  (Egan, 
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2005). In trial observations, after five injections of vaccine, about 50% recipient populations 
were found containing vaccine-specific immune responses and increased ability to neutralize 
laboratory-grown  HIV-1  as  well  (Bartlett  et  al.,  1998).  It  appeared  to  be  safe  and 
immunopotent. Clinical measures of HIV infection did not change in patients who received 
the peptide vaccine relative to individuals vaccinated with the placebo (Bartlett et al., 1998). 
Other  similar  vaccines  like  Vacc-4x,  developed  by  Norwegian  biotechnology  company 
Bionor Immuno, is currently being tested in an ongoing clinical trial in Norway. 
5.1.5 Vaccines Delivered through Viral Vectors
Currently,  live  viral  vectors  based  vaccines  (gene  carriers)  are  efficiently  being  used  to 
deliver enclosed HIV genes to host cells where they mimic like natural HIV infection and 
behave like potential  prophylactic HIV-1 vaccines. To deliver vaccines using Canary pox 
virus  (ALVAC),  Adenovirus type  5  (Ad5),  Adeno-Associated  Virus (AAV),  Venezuelan 
Equine Encephalitis Virus (VEE), Vesicular Stomatitis Virus (VSV) and Modified Vaccinia 
Virus Ankara (MVA) as vector are under evaluation (Egan, 2005).
5.1.6 Plasmid DNA Vaccine
In 1990, after demonstration of plasmid DNA expression in mouse muscle cells and eliciting 
vaccine-specific immune responses, many DNA vaccines against viral,  bacterial,  parasites 
infections  were  evaluated  in  animals  and  human  trials  and  found  to  be  well-tolerated. 
Considering these pioneering studies, the first human trial of a DNA-based vaccine carrying 
HIV-1  env and  rev genes for the treatment  of HIV-1 infection was attempted in 1998 at 
University  of  Pennsylvania  (MacGregor  et  al.,  1998)  to  evaluate  the  safety  and 
immunopotency of a plasmid DNA vaccine. Though, vaccine was safe and well-tolerated but 
only  marginal  increase  in  anti-env  immune  responses  was  elicited  with  no  measurable 
beneficial effect on clinical measures of HIV infection.
5.1.7 Antigen-pulsed Dendritic Cells
Dendritic cells (DCs), being key inducer of cellular immune response, are often used to load 
protein or peptide to which an immune response is desired, and infused back into the patient. 
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After finding it quite successful against cancer, its ability to augment HIV-specific immune 
responses is also been tested. In a pilot study, nine infusions of HIV-1 protein/peptide pulsed 
DCs in HIV-1-infected  individuals  were observed safe,  well  tolerated  and immunopotent 
(Kundu, 1998). However, larger placebo-controlled trials are required to determine if the use 
of antigen-loaded DCs can produce a measurable clinical benefit.
5.1.8 CTL-based Vaccines 
In these approaches HIV-specific CD4+ and CD8+ T cells  are stimulated with prepared 
gene-based  immunogens  that  are  modified  to  improve  protein  expression  and 
immunogenicity  to  arrest  the  HIV infection  (Nabel  et  al.,  1987). This  is  done  through 
insertion of HIV cDNAs into relevant plasmids possessing replication-defective forms of 
adenoviruses  and  poxviruses.  Therefore,  provide  great  flexibility  in  identification  of 
immunogens that can induce broad and potent CTL immune responses. Moreover, several 
mutants of gp160 and fusion intermediates’ analogues are also developed which can illicit 
CTL responses and enhanced antibody responses as well (Nabel et al., 1987)
5.2 What can be an ideal HIV vaccine?
An agent potent to ultimately grant the sterilizing immunity by eliciting the production of 
broadly cross-reactive  neutralizing  Abs,  block  viral  entry  to  host  cell  and  target  viral 
replication, can be an ideal prophylactic or therapeutic HIV vaccine. But weighty stones like 
poor accessibility of conserved receptor-binding sites, extensive glycosylation and antigenic 
variation of gp120 (Preston, 1997) are blocking the path to generate specific Abs eliciting 
vaccines. Hence, unable to target unique complex epitopes and trimeric fusion intermediates 
for efficient inhibition of virus binding and entry into host cell. 
5.3 Major roadblocks in HIV vaccine development 
Though plenty of attempts are made for developing safe and effective vaccine, and few are 
under trials but could have not been proved successful due to complex structure, life cycle 
and high mutation rate of HIV-1 which facilitate it for drug resistance and immune escape. 
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So  far,  12  known  HIV-1  genetic subtypes  rapidly  diversified  to  yield  intersubtype 
recombinants are identified existing in humans (Korber et al. 2001; McCutchan, 2000). 
Besides them, thermostably concealed conserved receptor- and coreceptor-binding sites on 
viral  envelope  (Myszka  et  al.  2000),  hidden  glycoprotein  (Kwong  et  al.  1998), 
conformational  flexibility  of  gp120  (Kwong  et  al.  2002),  high  error  rate  in  reverse 
transcription (Preston, 1997), diminished (Finzi et al.  1998) and variant (Ho et al. 1995) 
protein expression to get escaped from immune recognition (Evans et al. 1999; Parren et al. 
1999)  and  several  yet  to  discover  factors  are  stretching  the  goal  of  HIV  vaccine 
development farther from reach. 
6. Nanotechnology based approaches 
Recently,  after  successful  implementation  of  nanotechnology-based drug delivery  system 
against cancer (van Vlerken et al., 2006) the polymer-based nanoparticles, liposomes, nano-
emulsions, dendrimers and micellar technologies (Amiji et al. 2006) are being used in AIDS 
also  to  overcome  several  anatomical  &  physiological  barriers  and  transport  therapeutic 
agents locally at the site of HIV.  For example, Saquinavir,  a member of protease inhibitor 
class,  potent  to  inhibit  protease-mediated  cleavage  of  gag and  pol polyproteins  in  HIV 
genome, is encapsulated efficiently in biodegradable hydrophobic polymeric nanoparticles, 
made with poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) (Shah et al. 
2006)  and  therefore  finally  preventing  the  post-translational  processing  required  for 
maturation and spreading of virus.
7. Conclusions
Yield of more and more mutated viruses and depletion of host’s initial immune response has 
made the HIV harder nut to crack. A therapeutic vaccine, able to overcome the hide and 
latency  of  virus  and  elicit  de  novo  cellular  immunity  and  virus-neutralizing  antibody 
responses  is  the  need  of  hour.  Though,  certain  vaccine  candidates  in  recent  non-human 
primate experiments like combination of DNA vaccines with potent immunomodulators and 
improved viral vectors (such as recombinant vesicular stomatitis virus or adenovirus), multi-
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epitope peptide  vaccine and some other  have shown the promising effects  but few more 
honest approaches involving the recent technologies are urgently needed to win the race. 
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